secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001193125-25-173591
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen
--------------------------------------------------------------------------------

- New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.
- Prior $200M ATM agreement with TD Cowen terminated effective August 5, 2025.
- TD Cowen will receive up to 3.0% commission on gross proceeds of shares sold.
- Company not obligated to sell any shares; sales subject to company instructions and market conditions.
- Issuance will be made under existing S-3 shelf registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525173591/0001193125-25-173591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525173591/d42398d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer